Overall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut): Pooled analysis of two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT).

Erlotinib Versus Etoposide/Cisplatin With Radiation Therapy in Unresectable Stage III Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter, Randomized, Open-Label, Phase 2 Trial

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2020.11.026 ◽

2020 ◽

Author(s):

Ligang Xing ◽

Gang Wu ◽

Luhua Wang ◽

Jiancheng Li ◽

Jianhua Wang ◽

...

Keyword(s):

Lung Cancer ◽

Growth Factor Receptor ◽

Small Cell ◽

Phase 2 ◽

Small Cell Lung ◽

Open Label ◽

Phase 2 Trial ◽

Unresectable Stage ◽

Open Label Phase ◽

1320_PR: Subgroup analyses of patients with epidermal growth factor receptor (EGFR)-expressing tumors in SQUIRE: A randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin (GC) plus necitumumab (N) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC)

Journal of Thoracic Oncology ◽

10.1016/s1556-0864(16)30326-4 ◽

2016 ◽

Vol 11 (4) ◽

pp. S153 ◽

Cited By ~ 3

Author(s):

L. Paz-Ares ◽

M.A. Socinski ◽

J. Shahidi ◽

R.R. Hozak ◽

V. Soldatenkova ◽

...

Keyword(s):

Growth Factor Receptor ◽

Stage Iv ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

Phase Iii Study ◽

30MO ORIENT-3: A randomized, open-label, phase III study of sintilimab versus docetaxel in previously treated advanced/metastatic squamous non-small cell lung cancer (sqNSCLC)

Annals of Oncology ◽

10.1016/j.annonc.2020.10.517 ◽

2020 ◽

Vol 31 ◽

pp. S1428

Author(s):

Y. Shi ◽

L. Wu ◽

X. Yu ◽

P. Xing ◽

J. Zhou ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Open Label ◽

Open Label Phase ◽

Phase Iii Study ◽

Previously Treated

Prognostic Factors in Non-Small-Cell Lung Cancer (NSCLC) Patients with Epidermal Growth Factor Receptor (EGFR) Mutations: Data from the Randomized Phase III Study Compared Gefitinib with Carboplatin Plus Paclitaxel (NEJ002)

Annals of Oncology ◽

10.1016/s0923-7534(20)32317-6 ◽

2012 ◽

Vol 23 ◽

pp. xi116

Author(s):

Y. Minegishi ◽

K. Kobayashi ◽

M. Maemondo ◽

A. Inoue ◽

S. Sugawara ◽

...

Keyword(s):

Lung Cancer ◽

Growth Factor Receptor ◽

Small Cell ◽

Phase Iii ◽

Egfr Mutations ◽

Small Cell Lung ◽

Phase Iii Study ◽

Epidermal Growth ◽

Nsclc Patients

Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.7500 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 7500-7500 ◽

Cited By ~ 59

Author(s):

J. Jassem ◽

C. J. Langer ◽

D. D. Karp ◽

T. Mok ◽

R. J. Benner ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Open Label ◽

Phase Iii Trial ◽

Open Label Phase

PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung Cancer

Journal of Thoracic Oncology ◽

10.1097/jto.0000000000000366 ◽

2015 ◽

Vol 10 (1) ◽

pp. 134-142 ◽

Cited By ~ 75

Author(s):

Ralph G. Zinner ◽

Coleman K. Obasaju ◽

David R. Spigel ◽

Robert W. Weaver ◽

J. Thaddeus Beck ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

Phase Iii Study

Anti-epidermal-growth-factor-receptor agents and complete responses in the treatment of advanced non-small-cell lung cancer: a meta-analysis of 17 phase III randomized controlled trials

Current Medical Research and Opinion ◽

10.1185/03007995.2014.978448 ◽

2014 ◽

Vol 31 (1) ◽

pp. 25-33 ◽

Cited By ~ 4

Author(s):

Wei-Xiang Qi ◽

Shen Fu ◽

Qing Zhang ◽

Xiao-Mao Guo

Keyword(s):

Lung Cancer ◽

Meta Analysis ◽

Growth Factor Receptor ◽

Small Cell ◽

Phase Iii ◽

Controlled Trials ◽

Small Cell Lung ◽

Randomized Controlled ◽

92P ARCHER 1050: PHASE III RANDOMIZED STUDY OF 1ST-LINE DACOMITINIB (D) VS GEFITINIB (G) FOR ADVANCED (ADV) NON-SMALL CELL LUNG CANCER (NSCLC) IN PATIENTS (PTS) WITH ACTIVATING EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION(S)

Lung Cancer ◽

10.1016/s0169-5002(13)70311-8 ◽

2013 ◽

Vol 80 ◽

pp. S39-S40 ◽

Cited By ~ 2

Author(s):

T.S.K. Mok ◽

K. Nakagawa ◽

R. Rosell ◽

Y. Wu ◽

C. Trygstad ◽

...

Keyword(s):

Lung Cancer ◽

Growth Factor ◽

Egfr Mutation ◽

Randomized Study ◽

Growth Factor Receptor ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Osimertinib for pretreated epidermal growth factor receptor Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study

Translational Cancer Research ◽

10.21037/tcr.2017.03.27 ◽

2017 ◽

Vol 6 (S2) ◽

pp. S235-S238

Author(s):

Mie Kotake ◽

Tateaki Naito ◽

Akira Ono ◽

Hirotsugu Kenmotsu ◽

Haruyasu Murakami ◽

...

Keyword(s):

Lung Cancer ◽

Growth Factor ◽

Growth Factor Receptor ◽

Small Cell ◽

Phase 2 ◽

Small Cell Lung ◽

Open Label ◽

Phase 2 Study ◽

A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer

Annals of Oncology ◽

10.1093/annonc/mdw621 ◽

2017 ◽

Vol 28 (2) ◽

pp. 285-291 ◽

Cited By ~ 6

Author(s):

H. Yoshioka ◽

N. Katakami ◽

H. Okamoto ◽

Y. Iwamoto ◽

T. Seto ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Open Label ◽

Phase Iii Trial ◽

Open Label Phase ◽

Previously Treated